{"id":4342,"date":"2026-08-12T07:31:05","date_gmt":"2026-08-12T07:31:05","guid":{"rendered":"https:\/\/hkeemall.com\/?post_type=product&#038;p=4342"},"modified":"2026-11-15T14:07:17","modified_gmt":"2026-11-15T06:07:17","slug":"1787813877","status":"publish","type":"product","link":"https:\/\/hkeemall.com\/en\/product\/1787813877\/","title":{"rendered":"(10% off when purchasing multiple boxes) Japanese Mounjaro Weight-Loss Injection, Manjianle Tirzepatide, Long-Acting GIP\/GLP-1 Receptor Agonist for Lowering Cholesterol and Weight Loss"},"content":{"rendered":"<div class=\"mj-wrap\" style=\"max-width: 760px; margin: 0 auto; padding: 0 12px; color: #1c2328; font-family: 'PingFang TC','Hiragino Sans','Noto Sans TC','Microsoft JhengHei','Noto Sans JP',sans-serif; -webkit-font-smoothing: antialiased; line-height: 1.65; font-size: 15px; box-sizing: border-box;\">\n<style data-rm-block-id=\"block-1\">\n@import url(\"https:\/\/fonts.googleapis.com\/css2?family=Noto+Sans+TC:wght@400;500;600;700&family=Noto+Serif+JP:wght@600;700&display=swap\");<br \/>.mj-wrap *,.mj-wrap *::before,.mj-wrap *::after{box-sizing:border-box}<br \/>.mj-wrap table{width:100%;border-collapse:collapse;font-size:13px;margin:10px 0}<br \/>.mj-wrap th,.mj-wrap td{border:1px solid #e4dfd6;padding:8px 10px;vertical-align:top;text-align:left;white-space:normal;overflow-wrap:anywhere;word-break:break-word}<br \/>.mj-wrap th{background:#f3efe8;color:#1c2328;font-weight:600}<br \/>.mj-wrap img{max-width:100%;height:auto}<br \/>.mj-wrap .mj-specs-wrap{overflow:visible}<br \/>@media (max-width:640px){<br \/>  .mj-sheet-inner{padding:20px 14px 16px !important}<br \/>  .mj-title{font-size:19px !important}<br \/>  .mj-h{font-size:16px !important}<br \/>  .mj-kicker{letter-spacing:.12em !important;font-size:10px !important}<br \/>  .mj-wrap .mj-specs,<br \/>  .mj-wrap .mj-specs tbody,<br \/>  .mj-wrap .mj-specs tr{display:block;width:100%}<br \/>  .mj-wrap .mj-specs th,<br \/>  .mj-wrap .mj-specs td{display:block;width:100%;max-width:100%}<br \/>  .mj-wrap .mj-specs th{padding:12px 12px 2px !important;background:transparent !important;border:0 !important;font-size:12px !important;color:#2c5a52 !important}<br \/>  .mj-wrap .mj-specs td{padding:2px 12px 12px !important;border:0 !important;border-bottom:1px solid #e4dfd6 !important;font-size:13px !important;line-height:1.7 !important}<br \/>  .mj-wrap .mj-specs tr:last-child td{border-bottom:0 !important}<br \/>}<br \/><\/style>\n<article class=\"mj-sheet\" style=\"background: #fbf9f5; border: 1px solid #e4dfd6; border-radius: 24px; overflow: hidden; box-shadow: 0 1px 0 rgba(28,35,40,.04),0 18px 40px -24px rgba(28,35,40,.18);\">\n<div class=\"mj-bar\" style=\"height: 4px; background: #2c5a52;\" data-rm-block-id=\"block-2\"><\/div>\n<div class=\"mj-sheet-inner\" style=\"padding: 32px 36px 28px;\">\n<div class=\"mj-kicker\" style=\"display: flex; align-items: center; justify-content: center; flex-wrap: wrap; gap: 8px; margin: 0 0 18px; color: #2c5a52; font-size: 11px; font-weight: 600; letter-spacing: .18em; text-align: center;\" data-rm-block-id=\"block-3\">Direct overseas shipping (Direct shipping from Japan)<\/div>\n<h2 class=\"mj-title\" style=\"font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 24px; font-weight: bold; line-height: 1.4; text-align: center; margin: 0 0 12px; color: #1c2328;\" data-rm-block-id=\"block-4\">Manjaro Subcutaneous Injection of Ateos<\/h2>\n<h2 class=\"mj-title\" style=\"font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 24px; font-weight: bold; line-height: 1.4; text-align: center; margin: 0 0 12px; color: #1c2328;\" data-rm-block-id=\"block-5\">\u00a0Tixipetide, Manjianle, Slimming Injection, Weight-Loss Injection<\/h2>\n<h2 class=\"mj-title\" style=\"font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 24px; font-weight: bold; line-height: 1.4; text-align: center; margin: 0 0 12px; color: #1c2328;\" data-rm-block-id=\"block-6\"><span style=\"font-size: 16px;\">Mounjaro\u00ae Subcutaneous Injection ATEOS\u00ae<\/span><br \/>\n<span style=\"font-size: 15px; font-weight: 600;\">2.5 mg \/ 5 mg \/ 7.5 mg \/ 10 mg \/ 12.5 mg \/ 15 mg<\/span><\/h2>\n<p class=\"mj-keys\" style=\"margin: 0 auto 10px; max-width: 620px; text-align: center; color: #3f4a46; font-size: 14px; font-weight: 600; line-height: 1.7;\" data-rm-block-id=\"block-7\">Package Insert No. 2499422G1024_1_11 | Company Code 530471<br \/>\nRevised in May 2026 (10th Edition) \/ Revised in September 2026 (11th Edition)<\/p>\n<p class=\"mj-keys\" style=\"margin: 0 auto 18px; max-width: 620px; text-align: center; color: #2c5a52; font-size: 14px; font-weight: 600; line-height: 1.7;\" data-rm-block-id=\"block-8\">Long-acting GIP\/GLP-1 receptor agonists | Chilzepatide Injection | Type 2 Diabetes<\/p>\n<h2 style=\"text-align: center;\"><a href=\"https:\/\/hkeemall.com\/1787813600-2\/\">\u27a1\ufe0f Click to view the product instructions<\/a><\/h2>\n<figure class=\"mj-figure\" style=\"margin: 0 auto 24px; max-width: 100%; background: #fffcf8; border: 1px solid #e4dfd6; border-radius: 20px; padding: 12px;\" data-rm-block-id=\"block-9\"><a href=\"https:\/\/hkeemall.com\/wp-content\/uploads\/2026\/08\/1-21.webp\"><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-7007 size-full aligncenter\" style=\"width: 100%; height: auto; display: block;\" src=\"https:\/\/hkeemall.com\/wp-content\/uploads\/2026\/08\/1-21.webp\" alt=\"Mounjaro Weight-Loss Injection\" width=\"500\" height=\"500\" srcset=\"https:\/\/hkeemall.com\/wp-content\/uploads\/2026\/08\/1-21.webp 500w, https:\/\/hkeemall.com\/wp-content\/uploads\/2026\/08\/1-21-300x300.webp 300w, https:\/\/hkeemall.com\/wp-content\/uploads\/2026\/08\/1-21-150x150.webp 150w, https:\/\/hkeemall.com\/wp-content\/uploads\/2026\/08\/1-21-12x12.webp 12w, https:\/\/hkeemall.com\/wp-content\/uploads\/2026\/08\/1-21-450x450.webp 450w, https:\/\/hkeemall.com\/wp-content\/uploads\/2026\/08\/1-21-54x54.webp 54w\" sizes=\"(max-width: 500px) 100vw, 500px\" \/><\/a><\/figure>\n<p style=\"font-size: 16px; font-weight: bold; color: #1c2328; margin: 0 0 12px; font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif;\" data-rm-block-id=\"block-10\">Product Details \/ Approvals, etc.<\/p>\n<div class=\"mj-specs-wrap\" style=\"margin: 0 0 28px; border: 1px solid #e4dfd6; border-radius: 16px; background: #fffcf8;\">\n<table class=\"mj-specs\" style=\"height: 1087px;\" width=\"652\">\n<tbody>\n<tr>\n<th style=\"text-align: center;\" data-rm-block-id=\"block-11\">Japan Standard Commodity Classification Code<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-12\">872499<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: center;\" data-rm-block-id=\"block-13\">Pharmacological Classification Name<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-14\">Long-acting GIP\/GLP-1 receptor agonists<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: center;\" data-rm-block-id=\"block-15\">General Name<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-16\">Tirzepatide Injection (Tirzepatide)<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-17\">2.5mg<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-18\">Manjaro Subcutaneous Injection 2.5 mg Ateos<br \/>\nYJ 2499422G1024<br \/>\nApproved 30400AMX00420<br \/>\nSales Begin April 2023<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-19\">5mg<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-20\">Manjaro Subcutaneous Injection 5 mg, Ateos<br \/>\nYJ 2499422G2020<br \/>\nApproval 30400AMX00421<br \/>\nSales Begin April 2023<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-21\">7.5mg<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-22\">Manjaro Subcutaneous Injection 7.5 mg Ateos<br \/>\nYJ 2499422G3027<br \/>\nApproved 30400AMX00422<br \/>\nSales Begin June 2023<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-23\">10mg<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-24\">Manjaro Subcutaneous Injection 10 mg Ateos<br \/>\nYJ 2499422G4023<br \/>\nApproved 30400AMX00423<br \/>\nSales Begin June 2023<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-25\">12.5mg<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-26\">Manjaro Subcutaneous Injection 12.5 mg Ateos<br \/>\nYJ 2499422G5020<br \/>\nApproval 30400AMX00424<br \/>\nSales Begin June 2023<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-27\">15mg<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-28\">Manjaro Subcutaneous Injection 15 mg Ateos<br \/>\nYJ 2499422G6026<br \/>\nApproved 30400AMX00425<br \/>\nSales Begin June 2023<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-29\">Storage Instructions \/ Expiration Date<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-30\">Store at 2\u20138\u00b0C \/ 24 months<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-31\">Regulatory Classification<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-32\">\u2013<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-33\">Manufacturing and Sales Yuan<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-34\">Eli Lilly Japan K.K.<br \/>\n5-1-28 Isogami-dori, Chuo Ward, Kobe City<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-35\">Sales Yuan<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-36\">Tanabe Pharma Co., Ltd.<br \/>\n3-2-10 Doshomachi, Chuo Ward, Osaka City<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-37\">Packaging<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-38\">Various sizes: 0.5 mL \u00d7 2 sets<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: center;\" data-rm-block-id=\"block-39\">Shipping method<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-40\">Direct overseas shipping (Direct shipping from Japan)<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: center;\" data-rm-block-id=\"block-41\">Preparation and shipping time<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-42\">After verifying payment and prescription eligibility,<br \/>\nOrders are typically shipped within 4 to 7 business days.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<section class=\"mj-sec\" style=\"margin: 0 0 22px;\">\n<h3 class=\"mj-h\" style=\"margin: 0 0 10px; padding: 0 0 8px; border-bottom: 1.5px solid #2c5a52; font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 17px; font-weight: bold; color: #1c2328;\" data-rm-block-id=\"block-43\">1. Product hint<\/h3>\n<div class=\"mj-panel\" style=\"background: #f3efe8; border: 1px solid #e4dfd6; border-radius: 14px; padding: 16px 18px; color: #5e6560; font-size: 14px; line-height: 1.8;\">\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-44\">Conditions for Approval: A drug risk management plan must be developed and properly implemented.<\/p>\n<p style=\"margin: 0;\" data-rm-block-id=\"block-45\">Handling Instructions: Avoid freezing; store at 2\u20138\u00b0C in the dark. Do not use if frozen. When storing at room temperature, keep the product in its outer packaging at a temperature not exceeding 37\u00b0C and use within 21 days.<\/p>\n<\/div>\n<\/section>\n<section class=\"mj-sec\" style=\"margin: 0 0 22px;\">\n<h3 class=\"mj-h\" style=\"margin: 0 0 10px; padding: 0 0 8px; border-bottom: 1.5px solid #2c5a52; font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 17px; font-weight: bold; color: #1c2328;\" data-rm-block-id=\"block-46\">2. Product Characteristics and Mechanism of Action (18.)<\/h3>\n<div class=\"mj-panel\" style=\"background: #f3efe8; border: 1px solid #e4dfd6; border-radius: 14px; padding: 16px 18px; color: #5e6560; font-size: 14px; line-height: 1.8;\">\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-47\">This product is an agonist of both the GIP receptor and the GLP-1 receptor; it binds to and activates both receptors, promoting insulin secretion in a glucose-concentration-dependent manner. It is a 39-amino acid peptide containing a C20 fatty acid side chain that binds to endogenous albumin, thereby prolonging its half-life and ensuring sustained action.<\/p>\n<p style=\"margin: 0;\" data-rm-block-id=\"block-48\">Pharmacological Effects (based on administration of more than 15 mg once weekly for 28 weeks, including an assessment after gradual titration to steady state): Reduces fasting and postprandial blood glucose levels; promotes phase 1 and phase 2 insulin secretion in response to glucose; reduces fasting and postprandial glucagon levels; increases systemic insulin sensitivity (M value); delays gastric emptying (as indicated by acetaminophen Cmax and AUC; most pronounced after the first dose, with effects diminishing after 4 weeks of repeated administration).<\/p>\n<\/div>\n<\/section>\n<section class=\"mj-sec\" style=\"margin: 0 0 22px;\">\n<h3 class=\"mj-h\" style=\"margin: 0 0 10px; padding: 0 0 8px; border-bottom: 1.5px solid #2c5a52; font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 17px; font-weight: bold; color: #1c2328;\" data-rm-block-id=\"block-49\">3. Specifications and Properties (3.2)<\/h3>\n<div class=\"mj-panel\" style=\"background: #f3efe8; border: 1px solid #e4dfd6; border-radius: 14px; padding: 16px 18px; color: #5e6560; font-size: 14px; line-height: 1.8;\">\n<p style=\"margin: 0;\" data-rm-block-id=\"block-50\">All strengths are for injection: a clear or slightly milky, colorless to pale yellow to pale brown liquid. Strengths: 2.5, 5, 7.5, 10, 12.5, and 15 mg (Ateos pre-filled kits, 0.5 mL \u00d7 2 kits each).<\/p>\n<\/div>\n<\/section>\n<section class=\"mj-sec\" style=\"margin: 0 0 22px;\">\n<h3 class=\"mj-h\" style=\"margin: 0 0 10px; padding: 0 0 8px; border-bottom: 1.5px solid #2c5a52; font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 17px; font-weight: bold; color: #1c2328;\" data-rm-block-id=\"block-51\">4. Ingredient Information (3.1\/19.)<\/h3>\n<div class=\"mj-panel\" style=\"background: #f3efe8; border: 1px solid #e4dfd6; border-radius: 14px; padding: 16px 18px; color: #5e6560; font-size: 14px; line-height: 1.8;\">\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-52\"><strong style=\"color: #1c2328;\">3.1 Composition<\/strong>\u3000Chlorozepadide in 1 package: 2.5\/5\/7.5\/10\/12.5\/15 mg.<\/p>\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-53\">Excipients (same for all strengths): disodium hydrogen phosphate heptahydrate 0.7 mg, sodium chloride 4.1 mg, hydrochloric acid as needed, sodium hydroxide as needed.<\/p>\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-54\"><strong style=\"color: #1c2328;\">19.<\/strong> Generic Name: Tirzepatide (Tirzepatide) [JAN] Molecular Formula: C<sub>225<\/sub>H<sub>348<\/sub>N<sub>48<\/sub>O<sub>68<\/sub>\u3000Molecular weight: 4813.45 Appearance: white powder.<\/p>\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-55\">Residues 2 and 13 are 2-methyl-Ala, and the C-terminus is an amidated Ser; 1,20-docosanedioic acid is linked to Lys at position 20 via a Glu and two 8-amino-3,6-dioxooctanoic acid linkers. A synthetic peptide consisting of 39 amino acid residues.<\/p>\n<p data-rm-block-id=\"block-56\"><img decoding=\"async\" src=\"https:\/\/hkeemall.com\/wp-content\/uploads\/2026\/09\/530471_2499422G1024_1_11_fig03.gif\" alt=\"Structural Formula\" \/><\/p>\n<\/div>\n<\/section>\n<section class=\"mj-sec\" style=\"margin: 0 0 22px;\">\n<h3 class=\"mj-h\" style=\"margin: 0 0 10px; padding: 0 0 8px; border-bottom: 1.5px solid #2c5a52; font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 17px; font-weight: bold; color: #1c2328;\" data-rm-block-id=\"block-57\">5. Indications and Usage (4.\/5.)<\/h3>\n<div class=\"mj-panel\" style=\"background: #f3efe8; border: 1px solid #e4dfd6; border-radius: 14px; padding: 16px 18px; color: #5e6560; font-size: 14px; line-height: 1.8;\">\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-58\"><strong style=\"color: #1c2328;\">4. Efficacy or Effectiveness<\/strong>\u3000Type 2 Diabetes<\/p>\n<p style=\"margin: 0;\" data-rm-block-id=\"block-59\">5. This treatment should be considered only when adequate results have not been achieved after thoroughly implementing the basic dietary and exercise therapies for diabetes.<\/p>\n<\/div>\n<\/section>\n<section class=\"mj-sec\" style=\"margin: 0 0 22px;\">\n<h3 class=\"mj-h\" style=\"margin: 0 0 10px; padding: 0 0 8px; border-bottom: 1.5px solid #2c5a52; font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 17px; font-weight: bold; color: #1c2328;\" data-rm-block-id=\"block-60\">6. Dosage and Administration (6.\/7.)<\/h3>\n<div class=\"mj-panel\" style=\"background: #f3efe8; border: 1px solid #e4dfd6; border-radius: 14px; padding: 16px 18px; color: #5e6560; font-size: 14px; line-height: 1.8;\">\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-61\">For adults, the usual maintenance dose is 5 mg administered subcutaneously once weekly, calculated based on the amount of chilizepatide. However, treatment should begin with 2.5 mg once weekly, and the dose should be increased to 5 mg once weekly after 4 weeks.<\/p>\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-62\">The dose may be adjusted as appropriate based on the patient's condition; if a weekly dose of 5 mg is insufficient, the dose may be increased by 2.5 mg at intervals of at least 4 weeks. The maximum dose is 15 mg once weekly.<\/p>\n<ol style=\"margin: 0; padding-left: 20px;\">\n<li style=\"margin-bottom: 6px;\" data-rm-block-id=\"block-63\">7.1 Once a week; votes must be cast on the same day of the week.<\/li>\n<li style=\"margin-bottom: 6px;\" data-rm-block-id=\"block-64\">7.2 Missed Dose: If there are still 3 days (72 hours) or more until the next scheduled dose, administer the missed dose immediately; thereafter, continue with the original schedule. If there are less than 3 days remaining, skip this dose and wait until the originally scheduled date. When changing the day of the week or time, ensure there is an interval of at least 3 days (72 hours) since the last dose.<\/li>\n<li style=\"margin-bottom: 6px;\" data-rm-block-id=\"block-65\">7.3 If the patient cannot tolerate the medication due to gastrointestinal disturbances, consider reducing the dose or delaying the dose escalation.<\/li>\n<li data-rm-block-id=\"block-66\">7.4 Dose-dependent weight loss may occur; when increasing the dose, in addition to monitoring blood glucose control, attention should be paid to weight loss, and the decision to increase the dose should be made with caution.<\/li>\n<\/ol>\n<\/div>\n<\/section>\n<section class=\"mj-sec\" style=\"margin: 0 0 22px;\">\n<h3 class=\"mj-h mj-h-alert\" style=\"margin: 0 0 10px; padding: 0 0 8px; border-bottom: 1.5px solid #7a2e2e; font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 17px; font-weight: bold; color: #7a2e2e;\" data-rm-block-id=\"block-67\">7. Important Notes (8.\/9.\/10.\/11.\/20.)<\/h3>\n<div class=\"mj-panel mj-panel-alert\" style=\"background: #f7efe9; border: 1px solid #e4cfc6; border-radius: 14px; padding: 16px 18px; color: #6b3a34; font-size: 14px; line-height: 1.8;\">\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-68\"><strong style=\"color: #7a2e2e;\">8. Important Basic Precautions<\/strong><\/p>\n<ol style=\"margin: 0 0 12px; padding-left: 20px;\">\n<li data-rm-block-id=\"block-69\">8.1 This product is not an insulin substitute. Confirm insulin dependence prior to administration. There have been reports of acute hyperglycemia and diabetic ketoacidosis following a switch from insulin to a GLP-1 receptor agonist.<\/li>\n<li data-rm-block-id=\"block-70\">8.2 Monitor blood glucose and urine glucose levels regularly to assess effectiveness; if the treatment is not effective after 3 to 4 months, consider switching to a more appropriate treatment.<\/li>\n<li data-rm-block-id=\"block-71\">8.3 Long-acting formulations may continue to have an effect after discontinuation; therefore, attention must be paid to fluctuations in blood glucose levels, as well as the prevention and management of side effects.<\/li>\n<li data-rm-block-id=\"block-72\">8.4 Patients must be fully informed of the symptoms of hypoglycemia and how to manage them.<\/li>\n<li data-rm-block-id=\"block-73\">8.5 This medication may cause hypoglycemia; exercise caution when working at heights, driving, or performing similar activities.<\/li>\n<li data-rm-block-id=\"block-74\">Common precautions for other similar medications: acute pancreatitis, gastrointestinal disorders\/dehydration\/ acute kidney injury, thyroid symptoms, biliary tract disorders, decreased blood pressure, self-injection training and disposal, diabetic retinopathy; must not be used in combination with other chirzepatide formulations (such as Zepbound) or other GLP-1 receptor agonists; efficacy and safety when used in combination with DPP-4 inhibitors have not been established.<\/li>\n<\/ol>\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-75\"><strong style=\"color: #7a2e2e;\">9.<\/strong> Severe gastrointestinal disorders, history of pancreatitis, predisposition to hypoglycemia, severe diabetic retinopathy, history of abdominal surgery\/ history of intestinal obstruction, risk of aspiration under general anesthesia or deep sedation, women who may be pregnant must use contraception during treatment and for 1 month after the final dose; do not administer to pregnant women; use during breastfeeding requires careful consideration; not tested in children; use with caution in the elderly.<\/p>\n<p style=\"margin: 0 0 6px;\" data-rm-block-id=\"block-76\"><strong style=\"color: #7a2e2e;\">10.2 Precautions for Concomitant Use<\/strong>\u3000Diabetes medications (increased risk of hypoglycemia, especially sulfonylureas, rapid-acting insulin secretagogues, and insulin; consider reducing the dose); Oral contraceptives (effectiveness may be reduced during the initial phase of initiation or dose escalation; delayed gastric emptying); narrow-therapeutic-index oral medications such as warfarin (delayed Tmax; monitoring required).<\/p>\n<p style=\"margin: 8px 0 6px;\" data-rm-block-id=\"block-77\"><strong style=\"color: #7a2e2e;\">11.1 Serious Adverse Effects<\/strong>\u3000Hypoglycemia (frequency unknown); acute pancreatitis (less than 0.11 TP3T); cholecystitis (frequency unknown), cholangitis (less than 0.11 TP3T), cholestatic jaundice (frequency unknown); Allergic reactions, angioedema (frequency unknown); ileus (frequency unknown). Common: nausea, diarrhea, loss of appetite, etc.<\/p>\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-78\"><strong>20.<\/strong> To prevent freezing, store at 2\u20138\u00b0C away from light; do not use if frozen. Store in the original packaging at room temperature not exceeding 30\u00b0C and use within 21 days.<\/p>\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-79\">Plasma concentrations in Japanese patients with type 2 diabetes (Week 32):<\/p>\n<p data-rm-block-id=\"block-80\"><img decoding=\"async\" src=\"https:\/\/hkeemall.com\/wp-content\/uploads\/2026\/09\/530471_2499422G1024_1_11_fig01.gif\" alt=\"Plasma concentration\" \/><\/p>\n<p style=\"margin: 12px 0 8px;\" data-rm-block-id=\"block-81\">Cumulative incidence of major cardiovascular events (compared with dulaglutide):<\/p>\n<p data-rm-block-id=\"block-82\"><img decoding=\"async\" src=\"https:\/\/hkeemall.com\/wp-content\/uploads\/2026\/09\/530471_2499422G1024_1_11_fig02.gif\" alt=\"Cumulative Incidence of MACE\" \/><\/p>\n<p style=\"margin: 8px 0 0; font-size: 13px;\" data-rm-block-id=\"block-83\">In the cardiovascular outcomes trial, the change in HbA1c at Week 144 was: this drug, \u22121.80 \u00b1 1.37 (5,530 patients); dulaglutide, \u22120.93 \u00b1 1.36 (5,390 patients). The incidence of severe hypoglycemia was approximately 0.71 TP3T in both groups. Major adverse effects in the study drug group: nausea 23.31 TP3T, diarrhea 19.61 TP3T, and loss of appetite 16.01 TP3T.<\/p>\n<\/div>\n<\/section>\n<section class=\"mj-sec\" style=\"margin: 0 0 10px;\">\n<h3 class=\"mj-h mj-h-alert\" style=\"margin: 0 0 10px; padding: 0 0 8px; border-bottom: 1.5px solid #7a2e2e; font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 17px; font-weight: bold; color: #7a2e2e;\" data-rm-block-id=\"block-84\">8. Contraindications (2.)<\/h3>\n<div class=\"mj-panel mj-panel-alert\" style=\"background: #f7efe9; border: 1px solid #e4cfc6; border-radius: 14px; padding: 16px 18px; color: #6b3a34; font-size: 14px; line-height: 1.8;\">\n<ol style=\"margin: 0 0 12px; padding-left: 20px;\">\n<li style=\"margin-bottom: 6px;\" data-rm-block-id=\"block-85\">2.1 Patients with a history of allergy to any of the ingredients in this product<\/li>\n<li style=\"margin-bottom: 6px;\" data-rm-block-id=\"block-86\">2.2 Diabetic ketoacidosis, diabetic coma or precoma, patients with type 1 diabetes [Must be treated promptly with insulin; this product should not be administered.]<\/li>\n<li data-rm-block-id=\"block-87\">2.3 Emergency situations such as severe infections or surgery [Blood glucose should be managed with insulin preparations; this product is not suitable for use in these situations.]<\/li>\n<\/ol>\n<p style=\"margin: 0;\" data-rm-block-id=\"block-88\">This product must not be administered to pregnant women or women who may be pregnant. This product is a controlled substance and a prescription drug; it must be used only as prescribed by a physician. For details, refer to the original Japanese package insert.<\/p>\n<\/div>\n<\/section>\n<section class=\"mj-sec\" style=\"margin: 0 0 22px;\">\n<h3 class=\"mj-h\" style=\"margin: 0 0 10px; padding: 0 0 8px; border-bottom: 1.5px solid #2c5a52; font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 17px; font-weight: bold; color: #1c2328;\" data-rm-block-id=\"block-89\">21\u201326. Other Official Information<\/h3>\n<div class=\"mj-panel\" style=\"background: #f3efe8; border: 1px solid #e4dfd6; border-radius: 14px; padding: 16px 18px; color: #5e6560; font-size: 14px; line-height: 1.8;\">\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-90\"><strong style=\"color: #1c2328;\">21.<\/strong> A drug risk management plan must be developed and implemented.<\/p>\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-91\"><strong style=\"color: #1c2328;\">22.<\/strong> 2.5\/5\/7.5\/10\/12.5\/15 mg Ateos, 0.5 mL \u00d7 2 sets each.<\/p>\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-92\"><strong style=\"color: #1c2328;\">24.<\/strong> Eli Lilly Japan K.K. Medical Information Inquiries TEL: 0120-360-605 medical.lilly.com\/jp<br \/>\nTanabe Pharma Co., Ltd. Medication Consultation Center TEL: 0120-753-280<\/p>\n<p style=\"margin: 0;\" data-rm-block-id=\"block-93\"><strong style=\"color: #1c2328;\">26.<\/strong> Manufacturer and Distributor: Eli Lilly Japan K.K. \/ Distributor: Tanabe Pharma Co., Ltd. \u00ae: Registered trademark<\/p>\n<\/div>\n<\/section>\n<div class=\"mj-foot\" style=\"margin: 8px 0 0; padding: 18px 8px 4px; border-top: 1px solid #e4dfd6; text-align: center; color: #7a2e2e; font-size: 13px; line-height: 1.7;\" data-rm-block-id=\"block-94\">\u203b This page was translated by Hkeemall based on PMDA Package Insert 2499422G1024_1_11 and is not a substitute for a doctor\u2019s prescription or the original Japanese version.<br \/>\n<a style=\"color: #7a2e2e; font-weight: bold; text-decoration: underline;\" href=\"https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/530471_2499422G1024_1_11#HDR_ContraIndications\" target=\"_blank\" rel=\"noreferrer noopener\">Enter \"Manjalo\" in the PMDA \"Package Insert Information\" field to search for the original version<\/a><\/div>\n<\/div>\n<\/article>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Overseas Direct Shipping (Direct from Japan) Mounjaro\u00ae Subcutaneous Injection Ateos  Substitute for Exipartide  Manjiale  Slimming Injection  Weight-Loss Injection Mounjaro\u00ae Sub<\/p>\n<div class=\"klb-readmore post-buttons\"><a class=\"button rounded primary\" href=\"https:\/\/hkeemall.com\/en\/product\/1787813877\/\">Read More <i class=\"klbth-icon-right-arrow\"><\/i><\/a><\/div>","protected":false},"featured_media":7007,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[226],"product_cat":[78,77,39,23],"product_tag":[207],"class_list":["post-4342","product","type-product","status-publish","has-post-thumbnail","product_brand-eli-lilly","product_cat-78","product_cat-77","product_cat-medication","product_cat-allergies","product_tag-eli-lilly","first","instock","sale","featured","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"_links":{"self":[{"href":"https:\/\/hkeemall.com\/en\/wp-json\/wp\/v2\/product\/4342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hkeemall.com\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/hkeemall.com\/en\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/hkeemall.com\/en\/wp-json\/wp\/v2\/comments?post=4342"}],"version-history":[{"count":31,"href":"https:\/\/hkeemall.com\/en\/wp-json\/wp\/v2\/product\/4342\/revisions"}],"predecessor-version":[{"id":8270,"href":"https:\/\/hkeemall.com\/en\/wp-json\/wp\/v2\/product\/4342\/revisions\/8270"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hkeemall.com\/en\/wp-json\/wp\/v2\/media\/7007"}],"wp:attachment":[{"href":"https:\/\/hkeemall.com\/en\/wp-json\/wp\/v2\/media?parent=4342"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/hkeemall.com\/en\/wp-json\/wp\/v2\/product_brand?post=4342"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/hkeemall.com\/en\/wp-json\/wp\/v2\/product_cat?post=4342"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/hkeemall.com\/en\/wp-json\/wp\/v2\/product_tag?post=4342"}],"curies":[{"name":"Well played","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}